

Bordeaux PharmacoEpi



- Permanent team of > 40 staff
- Transparency and Quality
 - Respect of the ENCePP code of conduct
 - Quality Management System based on ISO 9001 principles
- > 30 field studies: 50 to 46 000 patients
- > 50 studies using national health insurance system databases
- > 100 publications for the past 5 years

Meet our Team Members at the 34th ICPE



université
de BORDEAUX



Inserm



Bordeaux PharmacoEpi Research Platform in Pharmacoepidemiology

At the 34th ICPE, Prague



Bordeaux PharmacoEpi
Plateforme de recherche en Pharmaco-épidémiologie
CIC Bordeaux CIC1401
INSERM – Université de BORDEAUX – CHU de Bordeaux – Adera
Bâtiment Le Tondu case 41 – 146 rue Léo Saigat - 33076 Bordeaux cedex

Oral Presentations*

(XXX) : Publication Number

Friday, August 24, 2018

Doacs, Doacs... and More Doacs

Panorama Hall
1:30pm - 3:00pm

Dr Patrick Blin

2:15pm

(15) Benefit-Risk Profile of Dabigatran compared with Vitamin-K Antagonists in Elderly Patients with Non-Valvular Atrial Fibrillation: a Cohort Study in the French Nationwide Claims Database. P. Blin, C. Dureau-Pournin, A. Abouelfath, R. Lassalle, J. Benichou, Y. Cottin, P. Mismetti, C. Droz-Perroteau and N. Moore



Heart, Blood, and Bleed

South Hall
5:00pm - 6:30pm

Régis Lassalle

5:00pm



(65) Direct Oral Anticoagulants versus Low-Molecular-Weight Heparins for venous thromboembolism prevention following total hip replacement: comparative effectiveness and medical costs from a French nationwide cohort study of around 120,000 patients. P. Blin, C-M. Samama, A. Sautet, P. Mismetti, J. Benichou, S. Lignot-Maleyran, S. Lamarque, S. Lorrain, R. Lassalle, A-F. Gaudin, F-E. Cotte, C. Droz-Perroteau and N. Moore

5:45pm

Pr Nicholas Moore

(68) Benefit-Risk of Rivaroxaban 20 or 15mg Compared to Vitamin-K Antagonists in Patients With Non-Valvular Atrial Fibrillation: a Cohort Study in the French Nationwide Claims Database. P. Blin, C. Dureau-Pournin, M-A Bernard, R. Lassalle, L. Fauchier, F. Sacher, J. Dallongeville, C. Droz-Perroteau and N. Moore



Posters and Oral presentation* also downloadable on
http://sibylle.pharmaco.u-bordeaux2.fr/congres/icpe_2018

* Downloadable after the oral presentation



Don't forget the **8th Bordeaux PharmacoEpi Festival**,
expected on **May, 2019**

Over three days, six world-class experts
will come to Bordeaux to talk of the topic of their choice.
Good Science, good Wine, good Fun!

More information soon on <http://pharmacoeppi.bordeaux-festival.eu>

Posters


(XXX) : Publication Number

Friday, August 24, 2018

Congress Foyer 3A




(151) Identifying patients with metastatic Castration-Resistant Prostate Cancers (mCRPC) in the SNDS database: CAMERRA study. N. Thurin, P. Blin, M. Rouyer, J. Jové, M. Gross-Goupil, T. Haaser, X. Rébillard, M. Soulié, C. Capone, C. Droz-Perroteau and N. Moore



(193) Outcomes of cetuximab in first line therapy for metastatic colorectal cancer according to tumor RAS-BRAF mutation status from an update of EREBUS cohort. M. Rouyer, P. Noize, D. Smith, E. François, A. Sa Cunha, Alain Monnereau, E. Yon, E. Bignon, C. Droz-Perroteau, N. Moore and A. Fourier-Réglat



(194) Evaluation of cabazitaxel in metastatic castration-resistant prostate cancer with real-life use, effectiveness, safety, and quality of life in the FUJI cohort. M. Rouyer, A. Fourier-Réglat, F. Tubach, S. Oudard, K. Fizazi, F. Joly, S. Lamarque, E. Guiard, A. Balestra, C. Lacueille, J. Jové, C. Droz-Perroteau and N. Moore



(195) Direct Oral Anticoagulants versus Low-Molecular-Weight Heparins for venous thromboembolism prevention following total knee replacement: comparative effectiveness and medical costs from a French nationwide cohort study of around 50 000 patients. P. Blin, C-M. Samama, A. Sautet, P. Mismetti, J. Benichou, S. Lignot-Maleyran, S. Lamarque, S. Lorrain, R. Lassalle, A-F. Gaudin, F-E. Cotte, C. Droz-Perroteau and N. Moore




Sunday, August 26, 2018

Congress Foyer 2A



(894) Effectiveness of ranibizumab intravitreal injections in visual impairment due to macular edema secondary to retinal vein occlusion: final results at 24 months from the French BOREAL cohort. P. Blin, C. Delcourt, A. Glacet-Bernard, C. Creuzot-Garcher, F. Fajnkuchen, J-F. Girmens, P-J. Guillausseau, L. Kodjikian, P. Massin, M. Mahe, R. Lassalle, M-A. Bernard, A. Chartier, H. Maizi, C. Droz-Perroteau, A. Grolleau, A. Grelaud and N. Moore



(1007) Benefit-Risk Profile of Dabigatran 110mg versus Vitamin-K Antagonists in Patients With Non-Valvular Atrial Fibrillation: a Cohort Study in the French Nationwide Claims Database. P. Blin, C. Dureau-Pournin, A. Abouelfath, R. Lassalle, J. Benichou, Y. Cottin, P. Mismetti, C. Droz-Perroteau and N. Moore



(1008) Benefit-Risk Profile of Dabigatran 150mg versus Vitamin-K Antagonists in Patients With Non-Valvular Atrial Fibrillation: Results From a Matched Cohort Study in the French Nationwide Claims Database. P. Blin, C. Dureau-Pournin, A. Abouelfath, R. Lassalle, J. Benichou, Y. Cottin, P. Mismetti, C. Droz-Perroteau and N. Moore

Meet also the **Eu2P** team at their booth!

EUROPEAN PROGRAMME IN
PHARMACOVIGILANCE AND PHARMACOEPIDEMOLOGY

The first European on-line training programme, more information on <https://www.eu2p.org>